3D Systems (DDD) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Mar, 2026Executive summary
Achieved a strong Q4 2025 finish with 16% sequential revenue growth, driven by new printer sales, materials, and momentum in aerospace & defense, personalized health services (PHS), and dental markets.
Focused on R&D investment, operational discipline, and cost savings, delivering $55M in annualized savings in 2025.
Divested Geomagic software business in April 2025, impacting year-over-year comparisons.
Recognized innovation in 3D-printed human lung and expanded U.S. facility to support aerospace & defense growth.
Net loss for Q4 narrowed significantly year-over-year, mainly due to gains on disposition and lower operating expenses.
Financial highlights
Q4 2025 consolidated revenue was $106.3M, up 3% year-over-year (adjusted for Geomagic), and up 16% sequentially from Q3.
Full year 2025 revenue was $386.9M, down 7% year-over-year (adjusted for Geomagic).
Q4 non-GAAP gross margin was 31%; full year non-GAAP gross margin was 34.3%.
Q4 adjusted EBITDA loss was $5.3M, a significant improvement year-over-year (adjusted for Geomagic).
Ended Q4 with $97.1M in total cash.
Outlook and guidance
Q1 2026 revenue expected between $91M–$94M; adjusted EBITDA loss of $5M–$3M.
Aerospace & defense expected to grow over 20% in 2026; PHS and dental segments also forecasted for continued growth.
Limiting guidance to Q1 2026 due to geopolitical and macroeconomic uncertainties.
Latest events from 3D Systems
- Revenue fell 8% YoY, net loss widened, but cost actions and asset sale strengthened liquidity.DDD
Q1 20259 Jul 2026 - Sequential revenue growth and margin gains offset year-over-year declines; outlook remains positive.DDD
Q2 20248 Jul 2026 - 2024 revenue hit $440M; cost cuts and Geomagic sale target break-even EBITDA by Q4 2025.DDD
Q4 20248 Jul 2026 - Plans to raise up to $100M for acquisitions and corporate needs, with broad risk disclosures.DDD
Registration filing22 May 2026 - Revenue up 11%, Healthcare surged 21%, and EBITDA turned positive on higher gross margin.DDD
Q1 202612 May 2026 - Board urges approval of all proposals, emphasizing the Equity Plan's role in talent retention.DDD
Proxy filing30 Apr 2026 - Proxy covers director elections, compensation, auditor, share increase, and incentive plan changes.DDD
Proxy filing8 Apr 2026 - Proxy seeks approval for board elections, compensation, auditor, share increase, and incentive plan.DDD
Proxy filing26 Mar 2026 - FDA-approved 3D printed dentures and aerospace growth position the business for major expansion.DDD
28th Annual Needham Growth Conference Virtual13 Jan 2026